

Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) - Global Forecast to 2028

<https://marketpublishers.com/r/A952778D7C4CEN.html>

Date: December 2023

Pages: 307

Price: US\$ 4,950.00 (Single User License)

ID: A952778D7C4CEN

Abstracts

The antibody therapeutics market is expected to reach USD 479.0 billion by 2028 from USD 247.3 billion in 2023, at a CAGR of 14.1% during the forecast period. The key factors driving the growth of the antibody therapeutics market include the increasing number of product approvals in the last five years and growing advancements in antibody engineering, among others. Moreover, growth avenues in emerging economies are an opportunity area for this market.

The antibody therapeutics market has been segmented based on format, disease area, route of administration, source, end user and region.

“By source, the human source segment accounted for the largest share of the antibody therapeutics market.”

Based on source, the antibody therapeutics market is categorized into human, humanized, chimeric and other sources. In 2022, humanized sources accounted for the highest growth rate owing to factors such as The rising demand for therapies (including antibody therapy) against cancer, increasing cancer prevalence, high effectiveness of humanized sourced antibodies against cancers and autoimmune & inflammatory diseases are the major factors driving the growth of this segment.

“By route of administration, the intravenous segment accounted for the largest share in the antibody therapeutics market.”

Based on the route of administration, the antibody therapeutics market is segmented into the intravenous, subcutaneous and other routes of administration. In 2022, the intravenous route segment accounted for the largest share of the antibody therapeutics market. Growth in this market segment can be attributed to ease of administration, high effectiveness, presence of large marketed products and major focus of pipeline products on intravenous route.

“North America: the largest share of the antibody therapeutics market.”

North America accounted for the largest share of the antibody therapeutics market. The large share of the North American region can be attributed to major factors such as presence of technologically advanced infrastructure in healthcare settings offering antibody therapeutics, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market. Also, the presence of some of the key players in the market is another key factor. Some examples of these players include AbbVie Inc. (US), Johnson & Johnson (US), and Bristol-Myers Squibb (US).

“Europe: The fastest-growing region in the antibody therapeutics market.”

The European antibody therapeutics market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for advancements of antibody therapeutics, increasing prevalence of chronic diseases and key players such as F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Sanofi (France) operating in the region.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45%, Directors- 30%, and Executives - 25%

By Region: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 3% & Africa- 2%

Prominent Players

F. Hoffmann-La Roche Ltd. (Switzerland)

AbbVie Inc. (US)

Johnson & Johnson (US)

Merck KGaA (Germany)

Bristol-Myers Squibb (US)

AstraZeneca (UK)

Sanofi (France)

Regeneron Pharmaceuticals, Inc. (US)

Novartis AG (Switzerland)

Amgen, Inc. (US)

Biogen Inc. (US)

Takeda Pharmaceutical Company Limited (Japan)

Pfizer Inc. (US)

Eli Lilly and Company (US)

Boehringer Ingelheim International GmbH (Germany)

GlaxoSmithKline plc (UK)

UCB, Inc. (Belgium)

Emergent BioSolutions Inc. (US)

Y-mAbs Therapeutics, Inc. (US)

Teva Pharmaceutical Industries Limited (Israel)

Ultragenyx Pharmaceutical Inc. (US)

Lundbeck A/S (Denmark)

Celltrion, Inc. (South Korea)

MacroGenics, Inc. (US)

MorphoSys AG (Germany)

Research Coverage:

This report provides a detailed picture of the antibody therapeutics market. It aims at estimating the size and future growth potential of the market across different segments, such as the format, disease area, route of administration, source, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the antibody therapeutics market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges. Additionally, the report is inclusive of extensive product mapping along with their revenues. The report also gives pipeline analysis of antibody therapeutic products which are expected to impact the market significantly during the forecast period.

The report provides insights on the following pointers”

Analysis of key drivers (growth in regulatory approvals for antibody therapeutics products), opportunities (emerging economies), restraint (stringent regulations) and challenges (manufacturing complexities) influencing the growth of the

antibody therapeutics market.

Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the antibody therapeutics market.

Market Development: Comprehensive information about lucrative markets- the report analyses the antibody therapeutics market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the antibody therapeutics market.

Analysis of clinical pipeline data and data on products estimated to be launched during the forecast period.

Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others in the antibody therapeutics market.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS AND EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

FIGURE 1 ANTIBODY THERAPEUTICS MARKET SEGMENTATION

1.3.2 YEARS CONSIDERED

1.4 CURRENCY CONSIDERED

1.5 STAKEHOLDERS

1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 2 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.2 PRIMARY DATA

FIGURE 3 ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES

2.2 MARKET SIZE ESTIMATION

FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS

FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS

2.2.1 INSIGHTS FROM PRIMARIES

FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS

FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH

2.3 GROWTH FORECAST

FIGURE 8 ANTIBODY THERAPEUTICS MARKET: CAGR PROJECTIONS

FIGURE 9 ANTIBODY THERAPEUTICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

2.4 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 10 DATA TRIANGULATION METHODOLOGY

2.5 RESEARCH ASSUMPTIONS

2.6 LIMITATIONS

2.7 RISK ANALYSIS

2.8 RECESSION IMPACT ANALYSIS

TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)

3 EXECUTIVE SUMMARY

FIGURE 11 ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2023 VS. 2028 (USD BILLION)

FIGURE 12 ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2023 VS. 2028 (USD BILLION)

FIGURE 13 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)

FIGURE 14 ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2023 VS. 2028 (USD BILLION)

FIGURE 15 ANTIBODY THERAPEUTICS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)

FIGURE 16 GEOGRAPHICAL SNAPSHOT OF ANTIBODY THERAPEUTICS MARKET

4 PREMIUM INSIGHTS

4.1 ANTIBODY THERAPEUTICS MARKET OVERVIEW

FIGURE 17 INCREASING DEMAND FOR ANTIBODY THERAPIES IN TREATMENT OF CANCER TO DRIVE MARKET

4.2 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE & COUNTRY (2022)

FIGURE 18 HUMAN SOURCES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022

4.3 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)

FIGURE 19 INTRAVENOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED MARKET IN 2022

4.4 ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 21 ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Advancements in antibody engineering

5.2.1.2 Rising demand for oncology therapeutics

TABLE 2 NUMBER OF APPROVED PRODUCTS BY US FDA/EMA (2015-2023)

5.2.1.3 Advantages offered by therapeutic antibodies

5.2.1.4 Increasing R&D activities for innovative therapeutics

5.2.2 RESTRAINTS

5.2.2.1 Stringent regulatory requirements

5.2.3 OPPORTUNITIES

5.2.3.1 High growth potential of emerging economies

5.2.3.2 Growing focus on collaborations for drug discovery & development

5.2.4 CHALLENGES

5.2.4.1 Complexities associated with manufacturing processes

5.3 PORTER'S FIVE FORCES ANALYSIS

TABLE 3 ANTIBODY THERAPEUTICS MARKET: PORTER'S FIVE FORCES ANALYSIS

5.3.1 THREAT OF NEW ENTRANTS

5.3.2 THREAT OF SUBSTITUTES

5.3.3 BARGAINING POWER OF SUPPLIERS

5.3.4 BARGAINING POWER OF BUYERS

5.3.5 INTENSITY OF COMPETITIVE RIVALRY

5.4 TECHNOLOGY ANALYSIS

5.5 VALUE CHAIN ANALYSIS

FIGURE 22 ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS

5.6 ECOSYSTEM ANALYSIS

FIGURE 23 ANTIBODY THERAPEUTICS MARKET: ECOSYSTEM MAP

5.7 PATENT ANALYSIS

FIGURE 24 PATENT APPLICATIONS FOR ANTIBODY THERAPEUTIC PRODUCTS (JANUARY 2012–OCTOBER 2023)

TABLE 4 ANTIBODY THERAPEUTICS MARKET: INDICATIVE LIST OF PATENTS

5.8 PIPELINE ANALYSIS

TABLE 5 ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE

5.9 SUPPLY CHAIN ANALYSIS

FIGURE 25 ANTIBODY THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS

TABLE 6 SUPPLY CHAIN ECOSYSTEM

5.10 REGULATORY LANDSCAPE

5.10.1 REGULATORY ANALYSIS

5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION

TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.11 PRICING ANALYSIS

5.11.1 AVERAGE SELLING PRICE TREND OF ANTIBODY THERAPEUTICS

TABLE 11 AVERAGE SELLING PRICE OF ANTIBODY THERAPEUTICS, BY KEY PLAYER

5.11.2 INDICATIVE PRICING ANALYSIS

TABLE 12 INDICATIVE PRICING ANALYSIS OF ANTIBODY THERAPEUTIC PRODUCTS, BY ROUTE OF ADMINISTRATION

5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.13 KEY CONFERENCES AND EVENTS

TABLE 13 ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023–2024)

5.14 KEY STAKEHOLDERS AND BUYING CRITERIA

5.14.1 KEY STAKEHOLDERS ON BUYING PROCESS

FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR ANTIBODY THERAPEUTICS

5.14.2 BUYING CRITERIA FOR ANTIBODY THERAPEUTICS MARKET

FIGURE 27 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES

6 ANTIBODY THERAPEUTICS MARKET, BY FORMAT

6.1 INTRODUCTION

TABLE 14 ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

6.2 MONOCLONAL ANTIBODIES

6.2.1 TARGET SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET

TABLE 15 APPROVED MONOCLONAL ANTIBODIES

TABLE 16 ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)

TABLE 17 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR

MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 18 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 19 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 20 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

6.3 POLYCLONAL ANTIBODIES

6.3.1 BROADER SPECTRUM OF TARGETS OFFERED BY POLYCLONAL ANTIBODIES TO SUPPORT MARKET GROWTH

TABLE 21 APPROVED POLYCLONAL ANTIBODIES

TABLE 22 ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)

TABLE 23 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 24 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 25 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 26 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

6.4 ANTIBODY FRAGMENTS

6.4.1 WIDE APPLICATIONS OF ANTIBODY FRAGMENTS IN ONCOLOGY TO FUEL GROWTH

TABLE 27 APPROVED ANTIBODY FRAGMENTS

TABLE 28 ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY REGION, 2021–2028 (USD MILLION)

TABLE 29 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 30 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 31 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 32 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)

6.5 BISPECIFIC ANTIBODIES

6.5.1 MINIMAL SIDE EFFECTS OF BISPECIFIC ANTIBODIES DUE TO TARGETED APPROACH TO FUEL ADOPTION

TABLE 33 APPROVED BISPECIFIC ANTIBODIES

TABLE 34 ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)

TABLE 35 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 36 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 37 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 38 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

6.6 OTHER NOVEL ANTIBODY THERAPIES

TABLE 39 APPROVED NOVEL ANTIBODY THERAPIES

TABLE 40 ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY REGION, 2021–2028 (USD MILLION)

TABLE 41 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 42 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 43 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 44 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)

7 ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA

7.1 INTRODUCTION

TABLE 45 ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

7.2 AUTOIMMUNE & INFLAMMATORY DISEASES

7.2.1 LARGE NUMBER OF MARKETED ANTIBODY THERAPEUTICS AND STRONG PIPELINE TO DRIVE MARKET

TABLE 46 ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2021–2028 (USD MILLION)

TABLE 47 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 48 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 49 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE

& INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 50 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

7.3 ONCOLOGY

7.3.1 INITIATIVES BY MARKET PLAYERS TO DEVELOP ANTIBODY THERAPIES FOR CANCER INDICATIONS TO SUPPORT GROWTH

TABLE 51 ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 52 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 53 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 54 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 55 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

7.4 HEMATOLOGY

7.4.1 GROWING PRODUCT ADOPTION TO SUPPORT MARKET GROWTH

TABLE 56 ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 57 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 58 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 59 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 60 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

7.5 INFECTIOUS DISEASES

7.5.1 GROWING RESEARCH FOCUS ON INFECTIOUS DISEASES TO FUEL MARKET GROWTH

TABLE 61 ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)

TABLE 62 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 63 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 64 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS

DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 65 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

7.6 OSTEOLOGY

7.6.1 GROWING FOCUS ON OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN TO SUPPORT GROWTH

TABLE 66 ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 67 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 68 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 69 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 70 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

7.7 IMMUNOLOGY

7.7.1 GROWING USE OF HUMORAL IMMUNODEFICIENCY ANTIBODY THERAPEUTICS TO PROPEL MARKET GROWTH

TABLE 71 ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 72 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 73 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 74 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 75 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

7.8 NEUROLOGY

7.8.1 PRESENCE OF SEVERAL MONOCLONAL ANTIBODIES FOR NEUROLOGICAL CONDITIONS TO FUEL MARKET GROWTH

TABLE 76 ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 77 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 78 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 79 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY,

BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 80 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

7.9 OTHER DISEASE AREAS

TABLE 81 ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION)

TABLE 82 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 83 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 84 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 85 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)

8 ANTIBODY THERAPEUTICS MARKET, BY SOURCE

8.1 INTRODUCTION

TABLE 86 ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

8.2 HUMAN

8.2.1 REDUCED IMMUNOGENICITY OF HUMAN-SOURCED ANTIBODIES TO DRIVE GROWTH

TABLE 87 ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY REGION, 2021–2028 (USD MILLION)

TABLE 88 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 89 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 90 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 91 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

8.3 HUMANIZED

8.3.1 EFFECTIVENESS OF HUMANIZED ANTIBODY THERAPEUTICS AGAINST CANCER AND AUTOIMMUNE & INFLAMMATORY DISORDERS TO DRIVE DEMAND

TABLE 92 ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY REGION, 2021–2028 (USD MILLION)

TABLE 93 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR

HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 94 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 95 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 96 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

8.4 CHIMERIC

8.4.1 INTRODUCTION OF HYBRID DESIGNS RESULTING IN IMPROVED EFFICACY TO SUPPORT MARKET GROWTH

TABLE 97 ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY REGION, 2021–2028 (USD MILLION)

TABLE 98 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 99 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 100 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 101 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

8.5 OTHER SOURCES

TABLE 102 ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2021–2028 (USD MILLION)

TABLE 103 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 104 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 105 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 106 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)

9 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

9.1 INTRODUCTION

TABLE 107 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

9.2 INTRAVENOUS

9.2.1 EFFECTIVENESS OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET

GROWTH

TABLE 108 ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)

TABLE 109 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 110 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 111 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 112 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

9.3 SUBCUTANEOUS

9.3.1 ADVANTAGES SUCH AS FASTER ONSET OF THERAPEUTIC EFFECT TO BOOST DEMAND

TABLE 113 ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)

TABLE 114 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 115 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 116 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 117 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

9.4 OTHER ROUTES OF ADMINISTRATION

TABLE 118 ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)

TABLE 119 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 120 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 121 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 122 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)

10 ANTIBODY THERAPEUTICS MARKET, BY END USER

10.1 INTRODUCTION

TABLE 123 ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

10.2 HOSPITALS

10.2.1 AVAILABILITY OF ADVANCED FACILITIES AND SUPPORT TO DRIVE MARKET

TABLE 124 ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)

TABLE 125 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 126 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 127 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 128 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)

10.3 LONG-TERM CARE FACILITIES

10.3.1 ADVANTAGES SUCH AS SPECIALIZED CARE AND MONITORING TO SUPPORT MARKET GROWTH

TABLE 129 ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2021–2028 (USD MILLION)

TABLE 130 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 131 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 132 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 133 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION)

10.4 OTHER END USERS

TABLE 134 ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)

TABLE 135 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 136 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 137 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 138 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)

11 ANTIBODY THERAPEUTICS MARKET, BY REGION

11.1 INTRODUCTION

TABLE 139 ANTIBODY THERAPEUTICS MARKET, BY REGION, 2021–2028 (USD MILLION)

11.2 NORTH AMERICA

FIGURE 28 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET SNAPSHOT

TABLE 140 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 141 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 142 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 143 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 144 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 145 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.2.1 US

11.2.1.1 Growing FDA approvals for novel antibody therapeutics to drive market

TABLE 146 US FDA ANTIBODY THERAPEUTIC PRODUCT APPROVALS

TABLE 147 US: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 148 US: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 149 US: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 150 US: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 151 US: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.2.2 CANADA

11.2.2.1 Growing cancer burden and investments in antibody research to support market growth

TABLE 152 CANADA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 153 CANADA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 154 CANADA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 155 CANADA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 156 CANADA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.2.3 NORTH AMERICA: RECESSION IMPACT

11.3 EUROPE

FIGURE 29 EUROPE: ANTIBODY THERAPEUTICS MARKET SNAPSHOT

TABLE 157 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 158 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 159 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 160 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 161 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 162 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.1 GERMANY

11.3.1.1 Rising incidence of cancer to drive market

TABLE 163 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 164 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 165 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 166 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 167 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY END USER,

2021–2028 (USD MILLION)

11.3.2 UK

11.3.2.1 Growing research initiatives to support market growth

TABLE 168 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040

TABLE 169 UK: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 170 UK: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 171 UK: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 172 UK: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 173 UK: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.3 FRANCE

11.3.3.1 Favorable reimbursement policies to drive growth

TABLE 174 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 175 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 176 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 177 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 178 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.4 ITALY

11.3.4.1 Growing regulatory approvals for antibody therapeutics to support growth

TABLE 179 ITALY: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 180 ITALY: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 181 ITALY: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 182 ITALY: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 183 ITALY: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.5 SPAIN

11.3.5.1 Growing prevalence of cancer to drive market

TABLE 184 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 185 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 186 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 187 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 188 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.6 REST OF EUROPE

TABLE 189 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 190 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 191 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 192 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 193 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.7 EUROPE: RECESSION IMPACT

11.4 ASIA PACIFIC

TABLE 194 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 195 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 196 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 197 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 198 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 199 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.1 CHINA

11.4.1.1 Growing demand for therapeutic products to support growth

TABLE 200 CHINA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028

(USD MILLION)

TABLE 201 CHINA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 202 CHINA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 203 CHINA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 204 CHINA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.2 JAPAN

11.4.2.1 Growing access to quality healthcare to boost market

TABLE 205 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 206 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 207 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 208 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 209 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.3 INDIA

11.4.3.1 Increasing burden of chronic diseases and growing R&D initiatives to drive market

TABLE 210 INDIA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 211 INDIA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 212 INDIA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 213 INDIA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 214 INDIA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.4 SOUTH KOREA

11.4.4.1 Favorable government initiatives to propel market

TABLE 215 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 216 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE

AREA, 2021–2028 (USD MILLION)

TABLE 217 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 218 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 219 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.5 REST OF ASIA PACIFIC

TABLE 220 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 221 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 222 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 223 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 224 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.6 ASIA PACIFIC: RECESSION IMPACT

11.5 LATIN AMERICA

TABLE 225 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 226 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 227 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 228 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 229 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 230 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.1 BRAZIL

11.5.1.1 Growing demand for therapeutics against chronic diseases to drive market

TABLE 231 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 232 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 233 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF

ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 234 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 235 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.2 REST OF LATIN AMERICA

TABLE 236 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 237 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 238 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 239 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 240 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.3 LATIN AMERICA: RECESSION IMPACT

11.6 MIDDLE EAST

11.6.1 DEVELOPING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET

TABLE 241 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 242 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 243 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 244 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 245 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.6.2 MIDDLE EAST: RECESSION IMPACT

11.7 AFRICA

11.7.1 INCREASING PUBLIC AND PRIVATE INVESTMENTS IN HEALTHCARE TO SUPPORT MARKET GROWTH

TABLE 246 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)

TABLE 247 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)

TABLE 248 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)

TABLE 249 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 250 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.7.2 AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION

12.2 KEY STRATEGIES/RIGHT TO WIN

FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY THERAPEUTICS MARKET

12.3 MARKET SHARE ANALYSIS

FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022

TABLE 251 DEGREE OF COMPETITION: ANTIBODY THERAPEUTICS MARKET

12.4 MARKET REVENUE ANALYSIS

FIGURE 32 REVENUE ANALYSIS FOR KEY COMPANIES, 2020–2022

12.5 COMPANY EVALUATION MATRIX

12.5.1 STARS

12.5.2 EMERGING LEADERS

12.5.3 PERVASIVE PLAYERS

12.5.4 PARTICIPANTS

FIGURE 33 COMPANY EVALUATION MATRIX, 2022

12.5.5 COMPANY FOOTPRINT

12.5.5.1 Product footprint

TABLE 252 PRODUCT FOOTPRINT OF KEY PLAYERS

12.5.5.2 Regional footprint

TABLE 253 REGIONAL FOOTPRINT OF KEY PLAYERS

12.6 START-UP/SME EVALUATION MATRIX

12.6.1 PROGRESSIVE COMPANIES

12.6.2 RESPONSIVE COMPANIES

12.6.3 DYNAMIC COMPANIES

12.6.4 STARTING BLOCKS

FIGURE 34 START-UP/SME EVALUATION MATRIX, 2022

12.6.5 COMPETITIVE BENCHMARKING

TABLE 254 DETAILED LIST OF KEY START-UPS/SMES

TABLE 255 COMPETITIVE BENCHMARKING OF START-UPS/SMES

12.7 COMPETITIVE SCENARIOS AND TRENDS

12.7.1 PRODUCT APPROVALS

TABLE 256 PRODUCT APPROVALS, JANUARY 2020–SEPTEMBER 2023

12.7.2 DEALS

TABLE 257 DEALS, JANUARY 2020–SEPTEMBER 2023

12.7.3 OTHER DEVELOPMENTS

TABLE 258 OTHER DEVELOPMENTS, JANUARY 2020–SEPTEMBER 2023

13 COMPANY PROFILES

(Business overview, Products/Services/Solutions offered, Recent developments & MnM View)*

13.1 KEY PLAYERS

13.1.1 F. HOFFMANN-LA ROCHE LTD.

TABLE 259 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW

FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)

TABLE 260 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES

TABLE 261 F. HOFFMANN-LA ROCHE LTD.: PRODUCT APPROVALS

TABLE 262 F. HOFFMANN-LA ROCHE LTD.: DEALS

13.1.2 ABBVIE INC.

TABLE 263 ABBVIE INC.: COMPANY OVERVIEW

FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2022)

TABLE 264 ABBVIE INC.: PRODUCT APPROVALS

TABLE 265 ABBVIE INC.: DEALS

13.1.3 JOHNSON & JOHNSON

TABLE 266 JOHNSON & JOHNSON: COMPANY OVERVIEW

FIGURE 37 JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 267 JOHNSON & JOHNSON: PRODUCT APPROVALS

13.1.4 MERCK KGAA

TABLE 268 MERCK KGAA: COMPANY OVERVIEW

FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022)

TABLE 269 MERCK KGAA: PRODUCT APPROVALS

TABLE 270 MERCK KGAA: OTHER DEVELOPMENTS

13.1.5 BRISTOL-MYERS SQUIBB

TABLE 271 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW

FIGURE 39 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2022)

TABLE 272 BRISTOL-MYERS SQUIBB: PRODUCT APPROVALS

TABLE 273 BRISTOL-MYERS SQUIBB: DEALS

TABLE 274 BRISTOL-MYERS SQUIBB: OTHER DEVELOPMENTS

13.1.6 ASTRAZENECA

TABLE 275 ASTRAZENECA: COMPANY OVERVIEW

FIGURE 40 ASTRAZENECA: COMPANY SNAPSHOT (2022)

TABLE 276 ASTRAZENECA: DEALS

TABLE 277 ASTRAZENECA: PRODUCT APPROVALS

13.1.7 SANOFI

TABLE 278 SANOFI: COMPANY OVERVIEW

FIGURE 41 SANOFI: COMPANY SNAPSHOT (2022)

TABLE 279 SANOFI: PRODUCT APPROVALS

TABLE 280 SANOFI: DEALS

13.1.8 REGENERON PHARMACEUTICALS INC.

TABLE 281 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW

FIGURE 42 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT

TABLE 282 REGENERON PHARMACEUTICALS INC.: DEALS

TABLE 283 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS

13.1.9 NOVARTIS AG

TABLE 284 NOVARTIS AG: COMPANY OVERVIEW

FIGURE 43 NOVARTIS AG: COMPANY SNAPSHOT (2022)

TABLE 285 NOVARTIS AG: DEALS

TABLE 286 NOVARTIS AG: PRODUCT APPROVALS

TABLE 287 NOVARTIS AG: OTHER DEVELOPMENTS

13.1.10 AMGEN INC.

TABLE 288 AMGEN INC.: COMPANY OVERVIEW

FIGURE 44 AMGEN INC.: COMPANY SNAPSHOT (2022)

TABLE 289 AMGEN INC.: DEALS

TABLE 290 AMGEN INC.: PRODUCT APPROVALS

TABLE 291 AMGEN INC.: OTHER DEVELOPMENTS

13.1.11 BIOGEN

TABLE 292 BIOGEN: COMPANY OVERVIEW

FIGURE 45 BIOGEN INC.: COMPANY SNAPSHOT (2022)

TABLE 293 BIOGEN: PRODUCT APPROVALS

TABLE 294 BIOGEN: DEALS

13.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED

TABLE 295 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW

FIGURE 46 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)

TABLE 296 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS

13.1.13 PFIZER INC.

TABLE 297 PFIZER INC.: COMPANY OVERVIEW

FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT

TABLE 298 PFIZER INC.: PRODUCT APPROVALS

13.1.14 ELI LILLY AND COMPANY

TABLE 299 ELI LILLY AND COMPANY: COMPANY OVERVIEW

FIGURE 48 ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 300 ELI LILLY AND COMPANY: PRODUCT APPROVALS

TABLE 301 ELI LILLY AND COMPANY: DEALS

TABLE 302 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS

13.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

TABLE 303 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW

FIGURE 49 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)

TABLE 304 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS

TABLE 305 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT APPROVALS

TABLE 306 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS

13.1.16 GLAXOSMITHKLINE PLC

TABLE 307 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW

FIGURE 50 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)

TABLE 308 GLAXOSMITHKLINE PLC: DEALS

TABLE 309 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS

TABLE 310 GLAXOSMITHKLINE PLC: OTHER DEVELOPMENTS

13.1.17 UCB S.A.

TABLE 311 UCB S.A.: COMPANY OVERVIEW

FIGURE 51 UCB S.A.: COMPANY SNAPSHOT (2022)

TABLE 312 UCB S.A.: DEALS

TABLE 313 UCB S.A.: PRODUCT APPROVALS

*Details on Business overview, Products/Services/Solutions offered, Recent developments & MnM View might not be captured in case of unlisted companies.

13.2 OTHER PLAYERS

13.2.1 EMERGENT BIOSOLUTIONS INC.

13.2.2 Y-MABS THERAPEUTICS, INC.

13.2.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.

13.2.4 ULTRAGENYX PHARMACEUTICAL INC.

13.2.5 H. LUNDBECK A/S

13.2.6 CELLTRION INC.

13.2.7 MACROGENICS, INC.

13.2.8 MORPHOSYS AG

14 APPENDIX

14.1 DISCUSSION GUIDE

14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

14.3 CUSTOMIZATION OPTIONS

14.4 RELATED REPORTS

14.5 AUTHOR DETAILS

I would like to order

Product name: Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/A952778D7C4CEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A952778D7C4CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970